Abstract: Provided is a method for areal selective forming of a thin film according to an exemplary embodiment of the present disclosure including: a substrate preparation step of supplying and stabilizing a substrate including a growth area and a non-growth area into a chamber; a precursor supply step of supplying a metal precursor compound into the chamber and adsorbing the metal precursor compound to the substrate; a purge step of purging the inside of the chamber; and a thin film formation step of supplying a reaction material into the chamber to react with the metal precursor compound and form a thin film, in which the metal precursor compound is a Group 5 metal precursor compound represented by Chemical Formula 1 below:

Abstract: The encapsulating composition according to the present invention comprises a radical-curable compound having at least one or more radical-curable functional groups, and has composition polarizability of 1.8 or less, wherein the composition polarizability is the sum of values obtained by multiplying each “compound polarizability of radical-curable compounds” constituting the encapsulating composition and “the weight ratio of the relevant radical-curable compound to the encapsulating composition” and the compound polarizability may be calculated by the following general equation 1.

Abstract: The invention of the present application relates to a use of an antibody binding specifically to ECL-2 of claudin 3 and functional fragments thereof in cancer cell detection, diagnosis, imaging, and application to cancer treatment (anticancer use of the antibody itself, and application to ADC and CAR-expression cells (particularly immune cells)), an antibody that includes a characteristic CDR sequence exerting a remarkable effect in such uses, and a functional fragment thereof.

Abstract: Disclosed are a pharmaceutical composition and a beauty-purposed pharmaceutical composition for prevention or treatment of neuromuscular disease, the composition including a combination of Erigeron annuus flower-based essential oil and Botox. Erigeron annuus flower-based essential oil inhibits t-SNARE protein and v-SNARE protein expression in neurons to inhibit the formation of SNARE protein complexes. Erigeron annuus flower-based essential oil inhibits the regeneration of t-SNARE protein and v-SNARE protein degraded by Botox to inhibit neurotransmitter release. Accordingly, an efficacy duration of Botox may be extended. Thus, Erigeron annuus flower-based essential oil may be usefully used in combination with Botox as Botox adjuvant for the prevention and treatment of neuromuscular disease or for beauty.

Abstract: Disclosed are a pharmaceutical composition and a beauty-purposed pharmaceutical composition for prevention or treatment of neuromuscular disease, the composition including a combination of Erigeron annuus flower-based essential oil and Botox. Erigeron annuus flower-based essential oil inhibits t-SNARE protein and v-SNARE protein expression in neurons to inhibit the formation of SNARE protein complexes. Erigeron annuus flower-based essential oil inhibits the regeneration of t-SNARE protein and v-SNARE protein degraded by Botox to inhibit neurotransmitter release. Accordingly, an efficacy duration of Botox may be extended. Thus, Erigeron annuus flower-based essential oil may be usefully used in combination with Botox as Botox adjuvant for the prevention and treatment of neuromuscular disease or for beauty.